A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Irinotecan (Primary) ; Cetuximab; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Adverse reactions
- 08 Dec 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jun 2015.
- 08 Dec 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2016.
- 08 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2016.